Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Table 6

(a) Primer sequence for qPCR. (b) Primer sequence for methylation analyses.

(a)

qPCR primer sequence
RASSF1A	Forward	5′-GCTGAGCGTCACGGCCAAGT-3′; 5′-ATGCTGAAGGCGTCCCAGTT-3′
	Reverse
MAGEA-1	Forward	5′-TCCGCCTTTCCCACTACCAT-3′; 5′-TCCAGCATTTCTGCCTTTGT-3′
	Reverse
MAGEA-3	Forward	5′-GGAGTCCGAGTTCCAAGCAG-3′; 5′-AGGCAGGTGGCAAAGATGTA-3′
	Reverse
P15	Forward	5′-CAACGGAGTCAACCGTTTCGG-3′; 5′-CAGCACCACCAGCGTGTCCAG-3′
	Reverse
p16	Forward	5′-CTGGACACGCTGGTGGTGCT-3′; 5′-CTATGCGGGCATGGTTACTGC-3′
	Reverse
BRCA1	Forward	5′-AGAAACCACCAAGGTCCAAA-3′; 5′-CCAAGGGTGAATGATGAAAG-3′
	Reverse
β-Actin	Forward	5′-AAAGACCTGTACGCCAACAC-3′; 5′-GTCATACTCCTGCTTGCTGAT-3′
	Reverse

(b)

Primer sequence
MAGEA-1 (M)	Forward	5′-AGGAGGGGATAAATATTTGGTTATAC-3′; 5′-GCTCAAATCAATAAAAAAAACGTC-3′
	Reverse
MAGEA-1 (U)	Forward	5′-AGGGGATAAATATTTGGTTATATGT-3′; 5′-CACTCAAATCAATAAAAAAAACATC-3′
	Reverse
MAGEA-3 (M)	Forward	5′-GGTAGTATCGTTGTTAGGATGTGAC-3′; 5′-AACCCTCTATCTAAAATAAAACCCG-3′
	Reverse
MAGEA-3 (U)	Forward	5′-GGTAGTATTGTTGTTAGGATGTGATG-3′; 5′-ACCCTCTATCTAAAATAAAACCCAC-3′
	Reverse